Eli Lilly Constructs Medicine Foundry in Lebanon

Eli Lilly and Company is constructing the $4.5 billion Lilly Medicine Foundry in Lebanon, Ind. The 1.2 million-sf center will combine research and advanced manufacturing with the latest technology to innovate new production methods and scale global access to medicines for clinical trials. Featuring a flexible layout, the seven-building complex will create various molecular therapies, including drug substances for small molecules, biologics, and nucleic acid therapeutics. 

The Medicine Foundry represents Lilly's most recent investment in the LEAP Innovation District, to which the company has committed a total of over $13 billion. The sophisticated facility’s strategic location will foster close collaboration with the company’s nearby teams and sites to accelerate progress while reducing costs and environmental impact. Once operational, the transformative hub is expected to dramatically reduce wait timelines for clinical trials, especially for participants with rare diseases.

Ground was broken in May of 2025 and production is slated to commence in 2027.